CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).
  
  OVERVIEW OF ACTIVITY
  The clinical course of CLL and outcomes for patients vary widely, largely according to individual predictive and other risk factors, and in recent years the identification of cytogenetic abnormalities and their subsequent incorporation into clinical staging systems have refined clinicians’ ability to determine prognosis. In addition, an improved understanding of the biology of CLL has led to the investigation of a number of novel agents and strategies. Some of these efforts have already resulted in the availability of new agents for use in the clinic. However, vexing questions and clinical challenges are emerging along with these many exciting advances.
  
  To bridge the gap between research and patient care, this program produced in partnership with the University of South Florida (USF Health) Office of Continuing Professional Development features a presentation by and an interview with a leading hematology-oncology investigator exploring relevant clinical research, published data sets and ongoing trials as well as a review of the results of a comprehensive survey consisting of case-based and practical management questions regarding the treatment of CLL. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.
  
  LEARNING OBJECTIVES

  • Recall the prognostic significance and clinical implications of select biomarkers and chromosomal abnormalities that may be associated with a diagnosis of chronic lymphocytic leukemia (CLL), and use this information to develop evidence-based testing algorithms in general oncology practice.
  • Evaluate current clinical algorithms employed by hematologic clinical investigators for patients with newly diagnosed and relapsed/refractory CLL.
  • Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase (BTK) inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to discern how this strategy can be optimally integrated into nonresearch treatment.
  • Recognize the FDA approval of venetoclax/obinutuzumab for CLL, and identify patients for whom this treatment strategy may be appropriate.
  • Compare and contrast the mechanisms of action, efficacy and safety of BTK inhibitors approved for the treatment of CLL to determine the current and/or potential utility of each in clinical practice.
  • Recognize the biologic rationale for, available research evidence with and ongoing clinical trials evaluating chemotherapy-free combinations for newly diagnosed and progressive CLL, and identify patients who may be candidates for these approaches outside or as part of ongoing research studies.

  CONTACT INFORMATION
  If you have questions regarding credit, please contact cpdsupport@usf.edu.
  
  

  ACCREDITATION STATEMENT
  USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice and USF Health aggregate deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
  
  FACULTY — The following faculty (and her spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Jennifer Woyach, MD
  Professor
  Section Head, CLL and Hairy Cell Leukemia
  Associate Division Director for Clinical Research
  Division of Hematology
  Department of Internal Medicine
  The Ohio State University Comprehensive Cancer Center
  Columbus, Ohio
  
  Advisory Committee: AbbVie Inc, ArQule Inc, Janssen Biotech Inc; Consulting Agreement: AbbVie Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  USF HEALTH CPD STAFF AND RESEARCH TO PRACTICE CME PLANNING COMMITTEE — Members, Staff, and Reviewers have no relevant conflicts to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Release date: November 2020
  Expiration date: November 2021